SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 65.52% | 98.84% | 138.92% | 141.13% | 8.10% |
| Total Depreciation and Amortization | -5.71% | -14.81% | -35.72% | -37.33% | -33.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -5,385.09% | -2,063.62% | -2,052.98% | -1,979.68% | -71.96% |
| Change in Net Operating Assets | -303.28% | -542.32% | -60.32% | 307.41% | 150.06% |
| Cash from Operations | -75.27% | -63.53% | -30.57% | 1.76% | 17.01% |
| Capital Expenditure | -2,149.33% | -820.51% | -176.67% | 84.16% | 53.49% |
| Sale of Property, Plant, and Equipment | 200.00% | 440.00% | -- | -- | -97.75% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,191.14% | -883.13% | -938.92% | -426.46% | 191.20% |
| Cash from Investing | -1,219.88% | -897.84% | -917.42% | -418.09% | 189.13% |
| Total Debt Issued | -- | -- | -- | -32.57% | -32.57% |
| Total Debt Repaid | 88.28% | 78.91% | 70.57% | 54.32% | -36.50% |
| Issuance of Common Stock | 261,099,700.00% | -- | 827,007.35% | 182.73% | -100.00% |
| Repurchase of Common Stock | 32.59% | 48.89% | 54.62% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96.80% | 99.15% | 99.69% | 100.00% | 89.41% |
| Cash from Financing | 32,509.92% | 27,239.42% | 14,453.88% | 154.44% | -101.21% |
| Foreign Exchange rate Adjustments | -1,532.29% | -41.55% | 11.53% | -258.84% | -206.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.76% | 277.25% | 103.36% | 200.23% | -243.13% |